A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 260 participants.
Also called NCT05737940
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 260 participants
- Sponsor
- Registry
-
NCT05737940
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Canada, China, Czechia, Denmark, Germany, Italy, Japan, Netherlands, Poland, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05737940. Randomized; triple masking; primary purpose treatment. Start 2023-04-24 (actual); primary completion 2025-07-15 (actual). Results posted on 2026-10-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
- Acronym
- Re-PHIRE
- Condition
- Pulmonary Hypertension (World Health Organization Group 2)
- Condition
- Heart Failure
- Intervention (Drug)
- AZD3427
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Parexel
Record details
- Record id
cardio:ct-nct05737940- Content hash
755aa3198779adc5725d9cf26c90e52d5d6090a8e0a23e8cebc40c0dd396a29d